p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer

被引：0
|
作者：
Norman Häfner
Kristin Nicolaus
Stefanie Weiss
Manfred Frey
Herbert Diebolder
Matthias Rengsberger
Matthias Dürst
Ingo B. Runnebaum
机构：
[1] Jena University Hospital,Department of Gynecology and Obstetrics
[2] Steinbeis-Transferzentrum Angewandte Biologische Chemie,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2013年 / 139卷
关键词：
Epithelial ovarian cancer; p53- autoantibody; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1207 / 1210
页数：3
相关论文
共 3 条
  • [1] p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer
    Haefner, Norman
    Nicolaus, Kristin
    Weiss, Stefanie
    Frey, Manfred
    Diebolder, Herbert
    Rengsberger, Matthias
    Duerst, Matthias
    Runnebaum, Ingo B.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1207 - 1210
  • [2] Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer
    Kim, Hee Seung
    Park, Noh-Hyun
    Chung, Hyun Hoon
    Kim, Jae Weon
    Song, Yong-Sang
    Kang, Soon-Beom
    ONKOLOGIE, 2008, 31 (06): : 315 - 320
  • [3] Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma
    Zeng, Jing
    Yin, Jie
    Song, Xiao
    Jin, Ying
    Li, Yan
    Pan, Lingya
    JOURNAL OF CANCER, 2016, 7 (15): : 2327 - 2332
1